Tuberculosis News and Research RSS Feed - Tuberculosis News and Research

Tuberculosis (TB) is a bacterial infection caused by a germ called Mycobacterium tuberculosis. The bacteria usually attack the lungs, but they can also damage other parts of the body. TB spreads through the air when a person with TB of the lungs or throat coughs, sneezes or talks. If you think you have been exposed, you should go to your doctor for tests as soon as possible. You are more likely to get TB if you have a weak immune system.
Dr. Rodrigo Guerrero becomes the first winner of Roux Prize

Dr. Rodrigo Guerrero becomes the first winner of Roux Prize

Dr. Rodrigo Guerrero, a Harvard-trained epidemiologist and mayor of Cali, Colombia, is the first winner of the Roux Prize, a new US$100,000 award for turning evidence into health impact and the largest prize of its kind. [More]
Study demonstrates longer-term benefits of Lung Flute for COPD patients

Study demonstrates longer-term benefits of Lung Flute for COPD patients

Patients with chronic obstructive pulmonary disease (COPD) report improved symptoms and health status when they use a hand-held respiratory device called the Lung Flute-, according to a new study by the University at Buffalo. Usually caused by smoking, COPD, which includes chronic bronchitis and emphysema, is the third leading cause of death in the U.S. [More]
New approach to create treatments for osteoporosis, autoimmune diseases

New approach to create treatments for osteoporosis, autoimmune diseases

Scientists have developed an approach to creating treatments for osteoporosis and autoimmune diseases that may avoid the risk of infection and cancer posed by some current medications. [More]
LSTM experts use integrated model to assess effects of new diagnostic algorithms for TB

LSTM experts use integrated model to assess effects of new diagnostic algorithms for TB

Experts at LSTM have used a novel modelling approach to project the effects of new diagnostic methods and algorithms for the diagnosis of tuberculosis (TB) recently endorsed by the World Health Organization, looking at the patient, health system and population perspective in Tanzania. [More]
New NIH program awards $2.5 million to spur innovation in mobile health

New NIH program awards $2.5 million to spur innovation in mobile health

A new NIH program is awarding nearly $2.5 million to spur innovation in mobile communication technologies and software applications used in biomedical research in low- and middle-income countries (LMICs). [More]
FDG-PET technology less accurate in diagnosing lung cancer in regions where infections are common

FDG-PET technology less accurate in diagnosing lung cancer in regions where infections are common

A new analysis of published studies found that FDG-PET technology is less accurate in diagnosing lung cancer versus benign disease in regions where infections like histoplasmosis or tuberculosis are common. Misdiagnosis of lung lesions suspicious for cancer could lead to unnecessary tests and surgeries for patients, with additional potential complications and mortality. [More]
New approach to diagnose tuberculosis

New approach to diagnose tuberculosis

Researchers working in the UK and The Gambia, have developed a new approach to the diagnosis of tuberculosis (TB) that relies on direct sequencing of DNA extracted from sputum (a technique called metagenomics) to detect and characterize the bacteria that cause TB without the need for time-consuming culture of bacteria in the laboratory. [More]
C-Path renews grant to advance more effective drug treatments for TB

C-Path renews grant to advance more effective drug treatments for TB

The Critical Path Institute, an independent, non-profit organization that works to accelerate the speed of drug and medical product development, today announced it has received a three-year grant renewal from the Bill & Melinda Gates Foundation. [More]
MIT engineers find new strategy to combat superbugs

MIT engineers find new strategy to combat superbugs

In recent years, new strains of bacteria have emerged that resist even the most powerful antibiotics. Each year, these superbugs, including drug-resistant forms of tuberculosis and staphylococcus, infect more than 2 million people nationwide, and kill at least 23,000. Despite the urgent need for new treatments, scientists have discovered very few new classes of antibiotics in the past decade. [More]

European research project develops low-cost, accurate urine test for TB detection

Tuberculosis (TB) is an infectious bacterial disease caused by Mycobacterium tuberculosis, which most commonly affects the lungs. Although it is curable and preventable it remains one of the world's top infectious killers. [More]
AbbVie’s Phase 3 pivotal study shows HUMIRA is effective in reducing symptoms in HS

AbbVie’s Phase 3 pivotal study shows HUMIRA is effective in reducing symptoms in HS

AbbVie today announced results from a Phase 3 pivotal study demonstrating that HUMIRA® (adalimumab) is effective in reducing common clinical signs and symptoms in moderate-to-severe hidradenitis suppurativa (HS), specifically the number of abscesses and inflammatory nodules. [More]
Fogarty receives three grants for research focused on biodiversity conservation

Fogarty receives three grants for research focused on biodiversity conservation

In addition to diseases for which there are ineffective or no cures, key pathogens are becoming increasingly drug-resistant. [More]
Scientists identify how molecular motor essential for human development works

Scientists identify how molecular motor essential for human development works

Another mystery of the human body has been solved by scientists who have identified how a molecular motor essential for human development works. [More]
SLU researchers work to prevent several serious infectious diseases

SLU researchers work to prevent several serious infectious diseases

Saint Louis University researchers are attacking influenza on multiple fronts as they search for a universal vaccine that protects people from the flu virus that often mutates year to year with deadly consequences. [More]
Canada funds 22 inventive ideas for improving health in low-resource countries

Canada funds 22 inventive ideas for improving health in low-resource countries

Grand Challenges Canada, funded by the Government of Canada, today announced $2.4 million in seed funds shared between 22 projects from Canada and nine developing nations, to pursue inventive new ideas for improving health in low-resource countries. [More]
Researchers identify different types of tuberculosis using new genetic barcode

Researchers identify different types of tuberculosis using new genetic barcode

Doctors and researchers will be able to easily identify different types of tuberculosis (TB) thanks to a new genetic barcode devised by scientists from the London School of Hygiene & Tropical Medicine. [More]

New genetic barcode helps identify different types of tuberculosis

Doctors and researchers will be able to easily identify different types of tuberculosis (TB) thanks to a new genetic barcode devised by scientists from the London School of Hygiene & Tropical Medicine. [More]
New blood test provides fast, accurate diagnosis of tuberculosis in children

New blood test provides fast, accurate diagnosis of tuberculosis in children

A new blood test provides a fast and accurate tool to diagnose tuberculosis in children, a new proof-of-concept study shows. The newly developed test (TAM-TB assay) is the first reliable immunodiagnostic assay to detect active tuberculosis in children. [More]
Research to determine breath test's effectivness in patient with COPD

Research to determine breath test's effectivness in patient with COPD

NYU Langone Medical Center will lead a new clinical initiative -- funded by a $225,000 grant from The National Institutes of Health -- to determine a breath test's effectivness to identify volatile organic compounds (VOCs) in human breath that are biomarkers of chronic obstrutive pulmonary disease (COPD). [More]
Cilag GmbH International acquires biopharmaceutical company, Covagen AG

Cilag GmbH International acquires biopharmaceutical company, Covagen AG

Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has acquired Covagen AG, a privately-held, biopharmaceutical company specializing in the development of multispecific protein therapeutics through the FynomAb® technology platform. [More]